BRPI0409926A - saposina c-dops: um agente antitumor - Google Patents

saposina c-dops: um agente antitumor

Info

Publication number
BRPI0409926A
BRPI0409926A BRPI0409926A BRPI0409926A BR PI0409926 A BRPI0409926 A BR PI0409926A BR PI0409926 A BRPI0409926 A BR PI0409926A BR PI0409926 A BRPI0409926 A BR PI0409926A
Authority
BR
Brazil
Prior art keywords
antitumor agent
saposin
dops
methods
compositions
Prior art date
Application number
Other languages
English (en)
Inventor
Xiaoyang Qi
Original Assignee
Childrens Hosp Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Childrens Hosp Medical Center filed Critical Childrens Hosp Medical Center
Publication of BRPI0409926A publication Critical patent/BRPI0409926A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"SAPOSINA C-DOPS: UM AGENTE ANTITUMOR". A presente invenção refere-se a composições e métodos para o tratamento de indivíduos com distúrbios caracterizados por hiperproliferação de células tais como tumores e cânceres. As composições compreendem agentes que são combinações de saposina C (ou polipeptídeos relacionados com prosaposina e dioleoilfosfatidilserina (ou componentes de folha pequena interna). Este agente antitumor é administrado nos métodos da invenção de acordo com um regime de dosagem. Administração de um agente da invenção resulta em uma resposta terapêutica positiva em um indivíduo com um tumor.
BRPI0409926 2003-04-28 2004-03-17 saposina c-dops: um agente antitumor BRPI0409926A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US46616603P 2003-04-28 2003-04-28
US10/801,517 US7834147B2 (en) 2003-04-28 2004-03-16 Saposin C-DOPS: a novel anti-tumor agent
PCT/US2004/008020 WO2004096159A2 (en) 2003-04-28 2004-03-17 Saposin c-dops: a novel anti-tumor agent

Publications (1)

Publication Number Publication Date
BRPI0409926A true BRPI0409926A (pt) 2006-04-25

Family

ID=33423597

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0409926 BRPI0409926A (pt) 2003-04-28 2004-03-17 saposina c-dops: um agente antitumor

Country Status (8)

Country Link
US (4) US7834147B2 (pt)
EP (1) EP1635856B1 (pt)
JP (1) JP4762132B2 (pt)
AU (2) AU2004233775C1 (pt)
BR (1) BRPI0409926A (pt)
CA (2) CA2911022C (pt)
ES (1) ES2828094T3 (pt)
WO (1) WO2004096159A2 (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7834147B2 (en) * 2003-04-28 2010-11-16 Childrens Hospital Medical Center Saposin C-DOPS: a novel anti-tumor agent
EP2020988B1 (en) * 2006-04-28 2017-08-16 Children's Hospital Medical Center Compositions comprising fusogenic proteins or polypeptides derived from prosaposin for application in transmembrane drug delivery systems
CN101541307A (zh) * 2006-10-20 2009-09-23 儿童医院医疗中心 自发形成的椭圆体磷脂单层囊泡
EP3127549B1 (en) * 2007-06-22 2019-12-18 Children's Medical Center Corporation Methods and uses thereof of a fragment of saposin a
AU2013203640B2 (en) * 2007-06-22 2017-04-13 Children's Medical Center Corporation Methods and uses thereof of prosaposin
EP2513137B1 (en) * 2009-12-17 2018-02-28 Children's Medical Center Corporation Saposin-a derived peptides and uses thereof
US9585972B2 (en) 2011-05-09 2017-03-07 Sherry L. Thornton Method for imaging a site of arthritis in an animal
CA2860226C (en) 2011-12-22 2022-10-18 Randolph S. Watnick Saposin-a derived peptides and uses thereof
WO2014078522A1 (en) 2012-11-14 2014-05-22 Ohio State Innovation Foundation Materials and methods useful for treating glioblastoma
ES2608857T3 (es) 2012-12-18 2017-04-17 Salipro Biotech Ag Partículas Salipro
EP3919070B1 (en) * 2013-03-14 2024-10-16 Children's Medical Center Corporation Use of cd36 to identify cancer subjects for treatment by a psap peptide
SI3043814T1 (sl) 2013-09-13 2021-04-30 Salipro Biotech AB, Greenhouse Labs Antigen in postopek za proizvodnjo le-tega
JP6727129B2 (ja) 2014-03-26 2020-07-22 ザ チルドレンズ メディカル センター コーポレーション 環状プロサポシンペプチドおよびその使用
US20180169120A1 (en) * 2016-11-21 2018-06-21 Bexion Pharmaceuticals, Inc. Combination therapy including sapc-dops for the treatment of pancreatic cancer
US20200237863A1 (en) 2017-10-16 2020-07-30 University Of Cincinnati Combination Therapy of Fractionated Radiation and SAPC-DOPS for the Treatment of Tumors
ES2980236T3 (es) 2017-10-16 2024-09-30 Univ Cincinnati Combinación de AS1411 y SAPC-DOPS para el tratamiento de glioblastoma multiforme
EP3768246B1 (en) 2018-03-23 2021-08-25 Bexion Pharmaceuticals, Inc. Saposin c pharmaceutical compositions and their use in treating cancer
CN120795059A (zh) 2018-08-27 2025-10-17 瑞泽恩制药公司 拉曼光谱在下游纯化中的应用
WO2021183595A1 (en) * 2020-03-10 2021-09-16 University Of Cincinnati Enhanced efficacy of combination of gemcitabine and phosphatidylserine-targeted nanovesicles against pancreatic cancer
WO2021183596A1 (en) * 2020-03-10 2021-09-16 University Of Cincinnati Materials and methods for the treatment of gaucher disease
EP4493189A1 (en) 2022-03-14 2025-01-22 Laekna Limited Combination treatment for cancer

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2002A (en) * 1841-03-12 Tor and planter for plowing
US2003A (en) * 1841-03-12 Improvement in horizontal windivhlls
US2001A (en) * 1841-03-12 Sawmill
NZ201918A (en) 1981-09-18 1987-04-30 Genentech Inc N-terminal methionyl analogues of bovine growth hormone
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4552811A (en) 1983-07-26 1985-11-12 Appleton Papers Inc. Capsule manufacture
US4588580B2 (en) 1984-07-23 1999-02-16 Alaz Corp Transdermal administration of fentanyl and device therefor
US4904475A (en) 1985-05-03 1990-02-27 Alza Corporation Transdermal delivery of drugs from an aqueous reservoir
GB8514665D0 (en) 1985-06-11 1985-07-10 Eroceltique Sa Oral pharmaceutical composition
US4873192A (en) 1987-02-17 1989-10-10 The United States Of America As Represented By The Department Of Health And Human Services Process for site specific mutagenesis without phenotypic selection
US4788062A (en) 1987-02-26 1988-11-29 Alza Corporation Transdermal administration of progesterone, estradiol esters, and mixtures thereof
US4816258A (en) 1987-02-26 1989-03-28 Alza Corporation Transdermal contraceptive formulations
JPS63250323A (ja) * 1987-04-03 1988-10-18 Nichirei:Kk 新規な制癌剤
US4927408A (en) 1988-10-03 1990-05-22 Alza Corporation Electrotransport transdermal system
CA2025907A1 (en) * 1989-09-21 1991-03-22 Franklin D. Collins Method of transporting compositions across the blood brain barrier
AU687755B2 (en) 1992-08-21 1998-03-05 Genentech Inc. Method for treating an LFA-1-mediated disorder
US5700909A (en) * 1993-07-30 1997-12-23 The Regents Of The University Of California Prosaposin and cytokine-derived peptides
HUT73527A (en) * 1993-08-13 1996-08-28 Seikagaku Kogyo Co Ltd Remedy for nervous diseases
DE69521880T2 (de) * 1994-02-08 2002-01-03 Amgen Inc., Thousand Oaks Orales verabreichungssystem von chemischmodifizierten proteinen g-csf
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
DE19541284C2 (de) * 1995-11-06 1998-09-24 Kalden Joachim Robert Prof Dr Verfahren zur Immunmodulation
US6271196B1 (en) * 1996-03-05 2001-08-07 Regents Of The University Of Ca Methods of alleviating neuropathic pain using prosaposin-derived peptides
EP0975330A1 (en) * 1997-02-04 2000-02-02 Abbott Laboratories Pain reducing parenteral liposome formulation
JP2001524944A (ja) * 1997-03-05 2001-12-04 ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア 神経障害性疼痛の緩和方法
WO1998042746A2 (en) * 1997-03-24 1998-10-01 Myelos Corporation Synthetic saposin c-derived neurotrophic peptides
US7341730B1 (en) * 1998-07-13 2008-03-11 University Of Southern California Inhibitors of angiogenesis and tumor growth
US20020177551A1 (en) 2000-05-31 2002-11-28 Terman David S. Compositions and methods for treatment of neoplastic disease
US6872406B2 (en) 2000-02-11 2005-03-29 Children's Hospital Research Foundation Fusogenic properties of saposin C and related proteins and polypeptides for application to transmembrane drug delivery systems
DE60125331T2 (de) 2000-02-28 2007-05-31 Bayer Healthcare Ag 27411, eine menschliche phosphatidyl-glycerinphosphate (pgp) synthase
AU2001241769A1 (en) 2000-02-29 2001-09-12 Millennium Pharmaceuticals, Inc. 32621, novel human phospholipid scramblase-like molecules and uses thereof
US7166691B2 (en) 2002-12-20 2007-01-23 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Saposin C and receptors as targets for treatment of benign and malignant disorders
US7834147B2 (en) * 2003-04-28 2010-11-16 Childrens Hospital Medical Center Saposin C-DOPS: a novel anti-tumor agent
EP2020988B1 (en) * 2006-04-28 2017-08-16 Children's Hospital Medical Center Compositions comprising fusogenic proteins or polypeptides derived from prosaposin for application in transmembrane drug delivery systems
CN101541307A (zh) 2006-10-20 2009-09-23 儿童医院医疗中心 自发形成的椭圆体磷脂单层囊泡
WO2012155147A2 (en) 2011-05-12 2012-11-15 Webtrends, Inc. Graphical-user-interface-based method and system for designing and configuring web-site testing and analysis

Also Published As

Publication number Publication date
WO2004096159A3 (en) 2005-09-01
US20040229799A1 (en) 2004-11-18
EP1635856A2 (en) 2006-03-22
EP1635856A4 (en) 2011-04-06
US20090269373A1 (en) 2009-10-29
US20190192623A1 (en) 2019-06-27
JP2006524681A (ja) 2006-11-02
CA2522833A1 (en) 2004-11-11
US20150125497A1 (en) 2015-05-07
AU2004233775B2 (en) 2009-10-22
AU2010200264A1 (en) 2010-02-25
US10188698B2 (en) 2019-01-29
CA2522833C (en) 2016-01-19
JP4762132B2 (ja) 2011-08-31
CA2911022C (en) 2021-07-20
EP1635856B1 (en) 2020-08-12
CA2911022A1 (en) 2004-11-11
US7834147B2 (en) 2010-11-16
WO2004096159A2 (en) 2004-11-11
US8937156B2 (en) 2015-01-20
AU2010200264B2 (en) 2013-02-14
AU2004233775C1 (en) 2010-03-18
AU2004233775A1 (en) 2004-11-11
ES2828094T3 (es) 2021-05-25

Similar Documents

Publication Publication Date Title
BRPI0410306A (pt) métodos para tratar, controlar ou evitar um cáncer especìfico, para tratar, controlar ou evitar uma doença associada com angiogênese indesejada e para reduzir ou evitar um efeito adverso, composição farmacêutica, e, kit
MX383644B (es) Combinaciones y metodos de administracion de agentes terapeuticos y terapia de combinacion.
BR0209114A (pt) Terapia de combinação usando agentes antiangiogênicos e tnfalfa
Zheng et al. Synergistic role of thymoquinone on anticancer activity of 5-fluorouracil in triple negative breast cancer cells
BRPI0409919A (pt) combinações para o tratamento de doenças envolvendo proliferação, migração ou apoptose celular de células de células de mieloma, ou angiogênese
BRPI0507644A (pt) pirazolopirimidinas como inibidores de cinase dependente de ciclina
ECSP055911A (es) Compuestos tricíclicos inhibidores de proteína quinasa para mejorar la eficacia de agentes antineoplásicos y terapia de radiación
BRPI0414908A (pt) compostos de benzazóis substituìdos, composições e métodos de inibição da atividade raf quinase em um humano ou animal
EA201200560A1 (ru) Специфическая терапия, использующая интегриновые лиганды для лечения рака
BRPI0511760A (pt) tratamento com gemcitabina e um inibidor de egfr
BR0206046A (pt) Usos de uma combinação e de sapogenina protopanaxadiol ou sapogenina protopanaxatriol, e, composição farmacêutica
NO20071426L (no) Kreft kombinasjonsbehandling omfattende AZD2171 og Imatinib
BR0316057A (pt) Métodos de tratar, controlar ou prevenir um câncer especìfico e uma doença associada com angiogênese indesejada e de reduzir ou evitar um efeito adverso associado com a administração de um segundo ingrediente ativo e com a terapia de radiação, terapia hormonal, terapia biológica ou imunoterapia em um paciente sofrendo de um câncer especìfico, composição farmacêutica e kit
CY1115782T1 (el) Φαρμακευτικες συνθεσεις για θεραπεια καρκινου
WO2004096159A3 (en) Saposin c-dops: a novel anti-tumor agent
WO2020061106A3 (en) Matter of composition, synthesis, formulation and application of fl118 platform positions 7 and 9-derived analogues for treatment of human disease
Hasan et al. Synthetic strigolactone analogues reveal anti-cancer activities on hepatocellular carcinoma cells
BRPI0510657A (pt) tratamento com cisplatina e com um inibidor de egfr
TW200630105A (en) Herbal composition PHY906 and its use in chemotherapy
EA200600921A1 (ru) Способы и композиции с применением талидомида для лечения и менеджмента рака и других заболеваний
BR112022000382A2 (pt) Administração de agonista de sting e inibidores de checkpoint
RU2010145048A (ru) On01910.na, усиливающий активность химиотерапевтического агента в резистентных к лекарственным средствам опухолях
Chunhu et al. Antiproliferative and apoptotic effects of paeonol on human hepatocellular carcinoma cells
PT1107795E (pt) Tiomolibdato associado com pelo menos um hidrato de carbono e o seu uso para evitar ou tratar doencas caracterizadas por uma vascularizacao tais como cancro degeneracao macular do tipo humido artrite reumatoide
BRPI0413410A (pt) co-administração de um polissacarìdeo com um agente quimioterapêutico para o tratamento de cáncer

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]